Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 40 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | June 2014 |
| End Date: | October 2016 |
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics
and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
Inclusion Criteria:
- Idiopathic Parkinson's disease, Hoehn and Yahr 1-3
- Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs
- Female subjects must be surgically sterile or post-menopausal or if of child-bearing
potential must use contraception
- Male subjects and their partners of childbearing potential must use contraception
Exclusion Criteria:
- Significant cardiac history
- Abnormal MRI
- Significant laboratory abnormalities
We found this trial at
8
sites
Compass Research LLC Compass Research is a clinical research company dedicated to testing new medications...
Click here to add this to my saved trials
Click here to add this to my saved trials
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials